Full title:Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) (TANGENT)
Age: 12+
Phase: 3
Locations:
- London – University College London Hospital
- Leeds – St James University Hospital
- Oxford – Churchill Hospital
Brief summary:
This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewed as an option.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.
